TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 12/29/23

2023-12-29 12:01:36 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Pfizer in 2024: What to expect? P...

2023-12-27 17:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-22 05:35:00 ET Dividend stocks that trade at cheap valuations can give investors multiple ways to profit from them. In addition to dividend income, you're also potentially setting yourself up for the possibility of profiting from a higher price in the future -- assuming, of course...

2023-12-21 16:15:19 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play Seagen lymphoma drug shows 100% progression free survival in Phase 2 t...

- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory * to Conventional Anti-CMV Treatment - Approval Based on Phase 3 TAK-620-303 SOLSTICE Study Demonstratin...

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema Canada NewsWire Availability of GLASSIA ® represents significant milestone for patients with emphysema due to severe hereditary defic...

2023-12-18 11:24:00 ET Summary Wave Life Sciences Ltd. raised $100 million in a discounted public offering, causing a decline in their stock price. The market reaction may have been incorrect, as the company has positive proof of concept data and major partnerships with Takeda and...

If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous At-Home or In-Office Treatment Option Positive Opinion Based on Phase 3 ADVANCE-CIDP 1 Study, Which Met its Primary Endpoint D...

2023-12-14 02:41:45 ET Japan ( NKY:IND ) -0.73%. Japan data: October Industrial Production (final) +1.3% (prior +0.5%). Japan October Machinery orders +0.7% m/m (vs. expected -0.5%). Markets also turned cautious ahead of the Bank of Japan’s policy meetin...